Mineralys Therapeutics, Inc. Common Stock (MLYS)
Mineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. The company utilizes proprietary technology to develop targeted treatments aimed at addressing unmet medical needs, with a particular emphasis on hyperkalemia. Mineralys aims to advance innovative solutions to improve patient outcomes in these therapeutic areas.
Company News
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
Mineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure across diverse high-risk patient populations with uncontrolled hypertension, with consistent safety and meaningful clinical results.
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 mi...
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.